ATE386942T1 - Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer - Google Patents
Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimerInfo
- Publication number
- ATE386942T1 ATE386942T1 AT04730881T AT04730881T ATE386942T1 AT E386942 T1 ATE386942 T1 AT E386942T1 AT 04730881 T AT04730881 T AT 04730881T AT 04730881 T AT04730881 T AT 04730881T AT E386942 T1 ATE386942 T1 AT E386942T1
- Authority
- AT
- Austria
- Prior art keywords
- diagnosis
- alzheimer
- disease
- prediction
- comparative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03447120A EP1480041A1 (de) | 2003-05-22 | 2003-05-22 | Verfahren zur Voraussage, zur Diagnose und zur vergleichenden Diagnose von Alzheimer |
US47762103P | 2003-06-11 | 2003-06-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE386942T1 true ATE386942T1 (de) | 2008-03-15 |
Family
ID=33041166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04730881T ATE386942T1 (de) | 2003-05-22 | 2004-05-03 | Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer |
Country Status (14)
Country | Link |
---|---|
US (2) | US20040265919A1 (de) |
EP (2) | EP1480041A1 (de) |
JP (1) | JP4769722B2 (de) |
AT (1) | ATE386942T1 (de) |
AU (1) | AU2004242203B2 (de) |
CA (1) | CA2525781C (de) |
CY (1) | CY1110252T1 (de) |
DE (1) | DE602004011931T2 (de) |
DK (1) | DK1625403T3 (de) |
ES (1) | ES2301986T3 (de) |
PL (1) | PL1625403T3 (de) |
PT (1) | PT1625403E (de) |
SI (1) | SI1625403T1 (de) |
WO (1) | WO2004104597A1 (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
EP1771715A4 (de) * | 2004-07-19 | 2009-04-22 | Mayo Foundation | Vorhersage der alzheimerkrankheit |
PE20061329A1 (es) | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体,其相关产品,生产所述抗体的方法,所述抗体的应用以及使用方法 |
RU2551782C2 (ru) | 2005-12-12 | 2015-05-27 | Ац Иммуне Са | Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами |
ES2409058T3 (es) * | 2006-04-13 | 2013-06-24 | Eidia Co., Ltd. | Método para someter a prueba la enfermedad de Alzheimer midiendo la tasa de degradación de beta-amiloide en sangre y reactivo de diagnóstico |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
WO2008011348A2 (en) | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
WO2008058760A1 (en) * | 2006-11-17 | 2008-05-22 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Method of differentially diagnosing dementias |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2486928A1 (de) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Verfahren zur Behandlung von Amyloidosen |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
PL2182983T3 (pl) | 2007-07-27 | 2014-10-31 | Janssen Alzheimer Immunotherap | Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta |
EP2586795B1 (de) | 2007-10-05 | 2018-05-16 | Genentech, Inc. | Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenkrankheiten |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
JP5607543B2 (ja) * | 2008-02-01 | 2014-10-15 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 治療に必要な軽度認知障害患者の特定方法とかかる患者の治療剤 |
MX2011000875A (es) | 2008-07-21 | 2011-04-05 | Probiodrug Ag | Ensayo de anticuerpo de diagnostico. |
AU2009295357A1 (en) * | 2008-09-26 | 2010-04-01 | The University Of Melbourne | Alzheimer's disease biomarkers |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
CN102612653A (zh) * | 2009-09-18 | 2012-07-25 | 前体生物药物股份公司 | 检测淀粉样蛋白β肽的新测定 |
TWI509246B (zh) * | 2009-12-11 | 2015-11-21 | Araclon Biotech Sl | 用於改良偵測澱粉樣β肽類之方法與試劑 |
DE102010014684A1 (de) * | 2010-04-09 | 2011-10-13 | Universität Duisburg-Essen | Neue Ansätze zur Alzheimer-Diagnose |
CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
CN103179981B (zh) | 2010-07-30 | 2017-02-08 | Ac免疫有限公司 | 安全和功能性的人源化抗β‑淀粉样蛋白抗体 |
CA2808187A1 (en) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Amyloid-beta binding proteins |
EP2511296A1 (de) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antikörper, Kit und Verfahren zur Bestimmung von Amyloidpeptiden |
JP6231263B2 (ja) * | 2012-07-17 | 2017-11-15 | 株式会社島津製作所 | アフィニティ支持体及びそれを用いた物質の捕捉方法 |
KR102076384B1 (ko) | 2012-08-16 | 2020-02-11 | 아이피어리언 인코포레이티드 | 타우병증을 치료하는 방법 |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
US10304006B2 (en) * | 2013-02-15 | 2019-05-28 | The Charles Stark Draper Laboratory, Inc. | Method for integrating and fusing heterogeneous data types to perform predictive analysis |
EP3104870A4 (de) | 2014-02-14 | 2017-09-13 | Ipierian, Inc. | Tau-peptide, anti-tau-antikörper und verfahren zur verwendung davon |
US20180252665A1 (en) * | 2014-05-27 | 2018-09-06 | Case Western Reserve University | System and methods for the detection of biomarkers of neurodegenerative disorders |
WO2015181391A1 (en) * | 2014-05-30 | 2015-12-03 | Biocross, S.L. | Method for the diagnosis of alzheimer's disease and mild cognitive impairment |
EP2950102A1 (de) * | 2014-05-30 | 2015-12-02 | Biocross, S.L. | Verfahren zur Diagnose von Morbus Alzheimer und milder kognitiver Beeinträchtigung |
CN113884683A (zh) * | 2020-07-30 | 2022-01-04 | 山东京济生物工程有限公司 | 一种快速检测Aβ42的双抗体夹心ELISA试剂盒 |
US20220260559A1 (en) * | 2020-11-04 | 2022-08-18 | Seer, Inc. | Biomarkers for diagnosing alzheimer's disease |
WO2022197651A1 (en) * | 2021-03-16 | 2022-09-22 | Neurovision Imaging, Inc. | Biofluid-based methods for diagnosing alzheimer's disease-associated conditions |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5262332A (en) * | 1989-04-05 | 1993-11-16 | Brigham And Women's Hospital | Diagnostic method for Alzheimer's disease: examination of non-neural tissue |
US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
EP0683234B2 (de) * | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
JP4357112B2 (ja) * | 1997-10-14 | 2009-11-04 | ルミネックス コーポレイション | 精密蛍光染色された粒子及びその製造及び使用方法 |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20020182660A1 (en) * | 2000-02-18 | 2002-12-05 | Fong Kei-Lai L. | N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43) |
PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
ES2228697T3 (es) * | 2001-06-12 | 2005-04-16 | Wiltfang, Jens | Anticuerpo monoclonal, mab 1e8, que es especifico para los dos primeros aminoacidos de peptidos beta-amiloides y su utilizacion en la deteccion de peptidos beta-amiloides y/o sapp alfa. |
DK1416965T3 (da) * | 2001-08-17 | 2008-05-05 | Univ Washington | Assayfremgangsmåde til Alzheimers sygdom |
-
2003
- 2003-05-22 EP EP03447120A patent/EP1480041A1/de not_active Withdrawn
-
2004
- 2004-05-03 ES ES04730881T patent/ES2301986T3/es not_active Expired - Lifetime
- 2004-05-03 AU AU2004242203A patent/AU2004242203B2/en not_active Ceased
- 2004-05-03 EP EP04730881A patent/EP1625403B1/de not_active Expired - Lifetime
- 2004-05-03 JP JP2006530173A patent/JP4769722B2/ja not_active Expired - Fee Related
- 2004-05-03 PT PT04730881T patent/PT1625403E/pt unknown
- 2004-05-03 DE DE602004011931T patent/DE602004011931T2/de not_active Expired - Lifetime
- 2004-05-03 WO PCT/EP2004/050684 patent/WO2004104597A1/en active IP Right Grant
- 2004-05-03 DK DK04730881T patent/DK1625403T3/da active
- 2004-05-03 CA CA2525781A patent/CA2525781C/en not_active Expired - Fee Related
- 2004-05-03 AT AT04730881T patent/ATE386942T1/de active
- 2004-05-03 SI SI200430701T patent/SI1625403T1/sl unknown
- 2004-05-03 PL PL04730881T patent/PL1625403T3/pl unknown
- 2004-05-19 US US10/848,686 patent/US20040265919A1/en not_active Abandoned
-
2007
- 2007-06-05 US US11/810,204 patent/US20080057593A1/en not_active Abandoned
-
2008
- 2008-05-20 CY CY20081100519T patent/CY1110252T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP2007522434A (ja) | 2007-08-09 |
CA2525781A1 (en) | 2004-12-02 |
DE602004011931T2 (de) | 2009-09-10 |
EP1480041A1 (de) | 2004-11-24 |
WO2004104597A1 (en) | 2004-12-02 |
EP1625403A1 (de) | 2006-02-15 |
PT1625403E (pt) | 2008-05-28 |
DK1625403T3 (da) | 2008-06-09 |
JP4769722B2 (ja) | 2011-09-07 |
CA2525781C (en) | 2013-08-13 |
US20080057593A1 (en) | 2008-03-06 |
SI1625403T1 (sl) | 2008-08-31 |
AU2004242203B2 (en) | 2008-12-11 |
US20040265919A1 (en) | 2004-12-30 |
ES2301986T3 (es) | 2008-07-01 |
AU2004242203A1 (en) | 2004-12-02 |
DE602004011931D1 (de) | 2008-04-03 |
CY1110252T1 (el) | 2015-01-14 |
PL1625403T3 (pl) | 2008-10-31 |
EP1625403B1 (de) | 2008-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE386942T1 (de) | Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer | |
DE60016178D1 (de) | Verfahren zur diagnose und zur charakterisierung von schlaganfall | |
WO2004001421A3 (en) | Method for the diagnosis and differential diagnosis of neurological diseases | |
DE60109311D1 (de) | Kit zur simultanen diagnose mehrerer ansteckender krankheiten und verfahren zu seiner herstellung | |
DE60233485D1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
WO2005061545A3 (en) | Nogoa antibodies for the treatment of alzheimer disease | |
DE60229051D1 (de) | Humanisierte antikörper | |
ATE475432T1 (de) | Arzneimittel für herzversagen | |
DE60331941D1 (de) | Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert | |
DE60224383D1 (de) | Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen | |
ATE523788T1 (de) | ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN | |
ATE314354T1 (de) | Radiopharmazeutika für die diagnose von alzheimer | |
DE60326153D1 (de) | Verfahren zur diagnose von morbus alzheimer | |
HK1056574A1 (en) | Materials and methods relating to protein aggregation in neurodegenerative disease | |
DE10295664D2 (de) | Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Paptide und deren Verwendungen | |
WO2002041842A3 (en) | Antibody pti-hs7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease | |
ZA200603178B (en) | Quick test for the diagnosis of Alzheimer's disease | |
DE60322768D1 (de) | Verfahren zur Herstellung von Partikeln für ein diagnostisches Reagenz | |
ATE465408T1 (de) | Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins | |
DE60216570D1 (de) | Verfahren zum nachweis von alzheimer-krankheit | |
IL172690A0 (en) | Methods for the diagnosis and prognosis of alzheimer's disease | |
WO2004001422A3 (en) | Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases | |
ATE352564T1 (de) | Spheron-komponenten für die bestimmung von verbindungen, die symptome der alzheimer krankheit behandeln können, ihre behandlungen und tiermodelle | |
WO2003104812A3 (en) | DIAGNOSIS ASSAY FOR ALZHEIMER'S DISEASE BASED ON THE DETERMINATION OF THE HA DOLLAR G (B) 42 RATE: HA DOLLAR G (B) 40 | |
ATE360094T1 (de) | Tcf-1 nukleotidsequenzvariation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1625403 Country of ref document: EP |